Studied doses
Tesamorelin Doses Studied in the Research Literature
What was administered, to whom, by which route, and for how long — recorded from the trials, framed as research context rather than guidance.
The gist
This page records the tesamorelin doses used in published research — it is not a how-to. In the major trials, the dose was 2 mg injected under the skin (subcutaneously) once a day; some studies tested a 1 mg arm. The injection went into the abdomen, and that was the only route studied. The drug is a freeze-dried powder mixed with liquid before use, kept refrigerated. Everything below describes what researchers gave to participants in specific populations. None of it is a dose for anyone to take, and research-grade material is not the approved medicine.
The studied regimen: 2 mg/day subcutaneous
The dose carried through both pivotal Phase 3 trials and the original FDA-approved regimen was 2 mg administered subcutaneously once daily [1][2][5]. That single regimen produced the headline results: visceral fat down 15.2% at 26 weeks [1] and sustained at -18% over 52 weeks [2]. The 2 mg once-daily paradigm is by far the most extensively studied, and it is the dose behind essentially every efficacy figure on this site.
A lower 1 mg subcutaneous daily arm appears in the research record. In the 12-week dose-ranging trial, 1 mg/day raised IGF-1 by 48% and 2 mg/day by 65% versus placebo, establishing the dose-response that informed the choice of 2 mg for the pivotal program [7]. A later reformulation of the approved product uses a higher-concentration once-daily subcutaneous regimen, but the once-daily 2 mg paradigm remains the well-characterized one. These are doses studied in HIV-associated lipodystrophy and related research cohorts — recorded here, not recommended.
Route and administration as studied
Subcutaneous injection at an abdominal site was the only route studied in clinical trials and is the only FDA-approved route [5]. There is no oral, intranasal, or other validated route in the published record for tesamorelin; the GHRH-analogue peptide is administered by subcutaneous injection in every trial that informs its use [1][2][3]. The reason is practical: as a 44-amino-acid peptide, tesamorelin would be degraded in the gut before absorption, so an injectable depot is the only delivery the evidence base covers.
The abdominal subcutaneous route matters mechanistically because absorption from that depot is what the population-PK analysis characterized — including the finding that the absorbed fraction rose about 13% by day 14 of daily dosing [8]. That same analysis found no clinically relevant demographic covariates shifting the pharmacokinetics, meaning the studied regimen behaved consistently across the trial populations regardless of age, sex, or body size [8]. This is a description of how the compound was delivered in research, not an instruction to administer it.
Half-life, frequency, and the once-daily rationale
Tesamorelin's plasma exposure is short. Population PK modeling reported apparent clearance of approximately 1,060 L/h with no clinically relevant demographic covariates [8], and secondary sources describe a terminal half-life on the order of 26-38 minutes. Despite that rapid clearance, the downstream IGF-1 elevation persists across the dosing interval, which is why once-daily administration was the regimen studied [4][9]. The fuller treatment is on the tesamorelin half-life and pharmacokinetics page.
The once-daily frequency, in other words, was chosen to match the biological signal rather than the plasma half-life — GH released in pulses, IGF-1 sustained across the day [9]. The dosing clock follows the effect, not the molecule.
Form, handling, and stability
Tesamorelin is supplied as a lyophilized powder requiring reconstitution before subcutaneous injection. The N-terminal trans-3-hexenoic acid modification is what blocks the DPP-IV cleavage that rapidly inactivates native GHRH, giving the molecule its biological stability in vivo. The FDA label specifies refrigerated storage and use of the reconstituted solution within a defined window.
A useful distinction sits in that last sentence: the molecule's stability in the body (conferred by the chemical modification) and the product's stability on the shelf (managed by refrigeration and a use-by window) are two different things. The first is intrinsic chemistry; the second is a handling requirement of a freeze-dried protein product.
Research-grade tesamorelin sold for laboratory use lacks the purity and potency oversight of the approved product, and is not the finished drug product. The handling notes here are drawn from the labeling of the studied product to describe how it is prepared, not to direct any human use.